Immunocore Holdings PLC 10-Q quarterly reports

Immunocore Holdings plc announced a significant increase in revenue and a return to net income for the second quarter of 2026, driven by strong KIMMTRAK sales.

Immunocore Holdings plc announced its first-quarter 2026 financial results, showcasing a 13.6% increase in total revenue driven by strong sales of its lead therapy, KIMMTRAK.

Immunocore Holdings plc reported strong 29.2% Q3 revenue growth from KIMMTRAK sales, alongside increased R&D investment and a net loss, as its pipeline progresses.

Immunocore Holdings plc announced significant revenue growth for its lead product KIMMTRAK and a substantial reduction in net loss for the second quarter and first half of 2025, driven by increased sales volume and global expansion.

Immunocore Holdings plc announces a 33% increase in revenue to $93.9 million for the first quarter of 2025, driven by strong sales of KIMMTRAK.

Immunocore Holdings reported a net income of $8.7 million for the third quarter of 2024, driven by a 28.1% increase in product revenue from KIMMTRAK sales.

Immunocore Holdings reported a 32.3% increase in product revenue for the second quarter of 2024, driven by sales of KIMMTRAK and progress in its clinical pipeline.

Immunocore Holdings saw a significant increase in product revenue in the first quarter of 2024, primarily driven by sales of its lead product, KIMMTRAK.